The size of the Kidney Cancer Diagnostics and Therapeutics Market in Europe was worth USD 0.87 billion in 2020 and estimated to be growing at a CAGR of 5.74%, to reach USD 1.15 billion by 2025.
Though there has been extensive progress in science and technology to tackle cancer, it continues to threaten lives across the world.
Kidney cancer is one of the recurrent urologic tumours accounting for around 3% of all the human cancers. The occurrence rate of renal cell carcinoma has increased progressively in recent decades.
Rise in Kidney cancer screening tests is one of the major drivers for the Kidney Cancer Diagnostics and Therapeutics market in this region. Another aspect is that European countries face comparable economic and demographic burdens and share an interest in scrutinizing their impact on health outcomes nationally and across Europe.
However, the high cost of Kidney cancer treatment is one of the main factors hindering the growth of this market in this region.
This research report on the Europe Kidney Cancer Diagnostics and Therapeutics Market is segmented and sub-segmented into the following categories:
By Type:
By Tests:
By Country:
On the basis of tests type, the Biopsy and CT Scan lead the tests segment in the Kidney Cancer Diagnostics and Therapeutics market accounting for more than 50% of the market.
Regionally, European is the third-largest market with a global share of 25%. The UK is the largest market shareholder for the Kidney Cancer Diagnostics and Therapeutics market in this region, followed by Germany and France.
Key players operating in the Europe Kidney Cancer Diagnostics and Therapeutics Market profiled in this report are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A, Hoffmann La Roche, Novartis and Abbott Laboratories.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Transitional Cell Cancer
5.1.2 Renal cell carcinoma
5.1.3 Renal sarcoma
5.1.4 Other Cancers
5.2 By Tests
5.2.1 Biopsy
5.2.2 CT Scan
5.2.3 Cystoscopy
5.2.4 Intravenous pyelogram
5.2.5 Kidney Ultrasound
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Bayer
9.3 Pfizer
9.4 Sanofi S.A
9.5 Hoffmann La Roche
9.6 Novartis
9.7 Abbott Laboratories
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
